Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

32 results about "SECRETOR FACTOR" patented technology

Single cell secretome analysis

Systems, methods, compositions, and kits for measuring secreted factors from cells are disclosed herein, including those capable of determining single cell secretion activity and protein expression and / or gene expression simultaneously. Disclosed herein include solid supports comprising a plurality of capture probes capable of specifically binding to at least one of the plurality of secreted factors secreted by a single cell. Also disclosed herein include secreted factor-binding reagents capable of specifically binding to a secreted factor bound by a capture probe. A secreted factor-binding reagent can comprise a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent.
Owner:BECTON DICKINSON & CO

Reprogrammed mesenchymal matrix-like cell and application of reprogrammed mesenchymal matrix-like cell in preparation of anti-aging drugs

The invention discloses a method for inducing fibroblasts to be reprogrammed into mesenchymal matrix-like cells (MLCs) by using small chemical molecules and application of the mesenchymal matrix-like cells (MLCs) in the anti-aging field. The invention discloses a set of specific chemical small molecule composition and an induction scheme thereof, which can be used for efficiently reprogramming fibroblasts from somatic cells into MLCs. Furthermore, the huge potential of the MLCs obtained by the method in anti-aging research is deeply explored, and the effect of the MLCs is proved to be obviously superior to that of umbilical cord mesenchymal stem cells in the aspects of reversing cell aging phenotypes and recovering tissue functions. The invention not only provides a new stem cell source strategy for avoiding the ethical and safety problems of the traditional reprogramming technology, but also lays a solid cell foundation for developing a novel, safe and effective anti-aging therapy based on cell transplantation or secreted factors.
Owner:HONGFANG BIOTECHNOLOGY (ZHENJIANG) CO LTD

Single cell secretome analysis

Systems, methods, compositions, and kits for measuring secreted factors from cells are disclosed herein, including those capable of determining single cell secretion activity and protein expression and / or gene expression simultaneously. Disclosed herein include solid supports comprising a plurality of capture probes capable of specifically binding to at least one of the plurality of secreted factors secreted by a single cell. Also disclosed herein include secreted factor-binding reagents capable of specifically binding to a secreted factor bound by a capture probe. A secreted factor-binding reagent can comprise a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent.
Owner:BECTON DICKINSON & CO

Method for producing hair follicle mesenchymal stem or progenitor cells, and application of same

The present invention addresses the problem of providing: a method for reprogramming differentiated hair follicle mesenchymal cells to produce stem or progenitor cells of the hair follicle mesenchymal cells; and a composition for preventing or ameliorating the thinning or graying of hair by using a secretion factor derived from the cells. A method for producing hair follicle mesenchymal stem or progenitor cells which solves the problem of the present invention is characterized by comprising bringing hair follicle mesenchymal cells into contact with a ROCK inhibitor in vitro. A composition that solves the problem of the present invention is characterized by containing an exosome or microRNA derived from the cells, and is capable of suppressing losing or graying of hair.
Owner:TAISHO PHARMACEUTICAL CO LTD +1

Potential protein capable of being used as anti-Alzheimer disease and anti-aging drug action target and application thereof

The invention discloses a potential protein capable of being used as an action target of an anti-Alzheimer disease and anti-aging drug and application of the potential protein. The application of the substance for exciting the fumaric acid hydrolase or increasing the expression of the fumaric acid hydrolase in preparing the medicine for treating the Alzheimer's disease or resisting aging is characterized in that the amino acid sequence of the fumaric acid hydrolase is as shown in SEQ ID NO. 1. The overexpressed FH can relieve the damage of senescence markers p21 and LamB1 in microglial cells and inhibit the expression of senescence-related secretory factors. The invention also discloses a novel pyrimidopyrrole micromolecule drug FH-9 which can be used as a micromolecule agonist for targeted excitation of FH, and the drug can excite the activity of FH at an in-vitro enzyme activity level, has a good anti-inflammatory effect, can improve cognitive impairment in AD mice, can improve various aging markers of aging microglia in vitro, and can be used for preparing an anti-inflammatory drug for treating AD mice. The traditional Chinese medicine composition has good anti-AD and anti-aging efficacy.
Owner:CHINA PHARM UNIV

Epicardial-derived paracrine factors for repairing cardiac tissue

To provide epicardial-derived paracrine factors for repairing cardiac tissue.SOLUTION: Provided herein is a composition and a kit comprising an epicardial-derived paracrine factor (e.g., hypoglycosylated follistatin-like 1 (FSTL1)) for treating and repairing damage to cardiac tissue caused by cardiovascular disease, myocardial infarction (MI), other ischemic events, or cardiac-growth deficiency, as well as a method for using them. In some aspects, a method for repairing a cardiac tissue (e.g., myocardial tissue) after injury in a subject in need thereof is provided, where the method comprises a step of contacting a cardiac tissue (e.g., myocardial tissue) with an epicardial-derived paracrine factor. In some embodiments, the epicardial-derived paracrine factor is hypoglycosylated follistatin-like 1 (FSTL1) polypeptide.SELECTED DRAWING: None
Owner:REGENCOR INC +1

Enhancement of extracellular protein transport from the Golgi apparatus to the extracellular space to increase the production of extracellular glucose oxidase in Pichia pastoris

The present invention provides a gene for increasing glucose oxidase (GOD) production in Pichia pastoris and its use. Specifically, the present invention provides a method for constructing a glucose oxidase (GOD)-producing strain, wherein the activity of a vesicle secretion-promoting factor is enhanced or a vesicle secretion-promoting factor is introduced into the starting strain. Experiments have confirmed that co-expression of the VAMP4 gene, which is involved in the vesicle transport pathway from the Golgi apparatus to the plasma membrane, significantly increases extracellular GOD production in Pichia pastoris.
Owner:EAST CHINA UNIV OF SCI & TECH

Method for enhancing the efficacy of stem cells by using ethionamide

The present invention relates to a culture medium composition for enhancing stem cell efficacy, comprising ethionamide; a method for enhancing stem cell efficacy and a method for producing stem cells with enhanced efficacy, comprising the step of culturing stem cells in the culture medium composition; stem cells produced by the method and uses thereof. According to the present invention, a simple process of treating mesenchymal stem cells with ethionamide can effectively enhance the anti-inflammatory effect of the mesenchymal stem cells and the expression level of paracrine factors, and the stem cells obtained by the method can be used to prevent or treat inflammatory diseases or degenerative brain diseases.
Owner:SAMSUNG LIFE PUBLIC WELFARE FOUND

Novel ras inhibitors

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders inflammatory diseases and / or genetic disorders. The present invention relates further to a pharmaceutical composition comprising the compounds of formula (I). Moreover, the present invention relates to a method of inhibiting growth, proliferation or metastasis of cancer cells in a subject in need thereof, in particular which may encompass subsets of patients defined by their mutational status of the RAS oncogene or patients who might have developed resistance to the standard of care or treatment with RAS mutation specific inhibitors. The present invention also relates to a method of inhibiting RAS molecules in treating genetic disorders like RASopathies or inflammatory disorders like Adenomyosis where KRAS gene is mutationally activated. In addition, the present invention relates to a method of inhibiting proliferation and or secretion of factors from a cell population sensitive towards inhibiting RAS activation in vitro, in particular sensitive towards inhibiting KRAS, HRAS and NRAS activation in vitro. Furthermore, the present invention relates to a kit containing a formulation comprising a pharmaceutical composition comprising a compound of formula (I).
Owner:KHR BIOTEC GMBH

Compositions and methods for treating hypertension by modulating endocrine activity

PCT designated stageWO2025207315A1CatheterBiological testingDiseaseAnti hypertension
Disclosed herein are compounds and ligands, and antihypertensive compositions formed therewith, that modulate seminal endocrine factors that control blood pressure and, thereby, treat hypertension. Also disclosed herein are methods for using the antihypertensive compositions to treat hypertension and disorders associated therewith.
Owner:OLFACTIVE AI INC

Application of pilose antler-derived substance in preparation of medicine for treating cerebral ischemia injury

The invention relates to the technical field of biological medicines, and particularly discloses application of a pilose antler-derived substance in preparation of a medicine for treating cerebral ischemia injury. The cornu cervi pantotrichum-derived substance comprises a cornu cervi pantotrichum extract AVE and a cornu cervi pantotrichum stem cell paracrine factor AnSC-CM. The AnSC-CM and AVE provided by the invention can reduce the water content of injured brain tissues of rats, reduce the brain injury area of the rats and repair central nervous injury of the rats, and the effect of the AnSC-CM is superior to that of the AVE.
Owner:长春科技学院

Cell culture applications using separate well microplates

A method for automating horizontal co-culture of cells using a single separated well microplate is presented. The present disclosure also presents an improved method for quantifying secreted factors from cultured cells, and a method for isolating target cells from organoids in a single separated well microplate. The use of a separated well microplate allows cell culture, cell washing, and (adult) stem cell capture in a single separated well microplate without the need for additional plates or special washing equipment. The use of a separated well microplate also allows multiple readings to be read simultaneously in a kinetic manner.
Owner:MOLECULAR DEVICES AUSTRIA GMBH +1

Composition comprising furin-inhibited car macrophages and uses thereof

CAR macrophages (CAR-M) can phagocyte tumor cells expressing a target antigen. It is herein shown that the proprotein convertase furin is over-expressed in human primary macrophages in the presence of tumor cells, which is a way to redirect these macrophages towards an anti-inflammatory phenotype. Conversely, inhibition of furin leads to the maintenance of their pro-inflammatory phenotype, even in a tumor cell environment. The present invention proposes to use furin-inhibited CAR-M derived from primary blood monocytes as a therapeutic strategy to treat solid tumors. Surprisingly, the generated furin-inhibited CAR-M display enhanced anti-tumor phagocytic activity against breast cancer cell lines and breast cancer patient-derived tumoroids and a persistent pro-inflammatory phenotype compared to furin-expressing CAR-M. Moreover, it was found that furin-inhibited CAR-M secreted factors can enhance T-cell proliferation and can thereby modulate the tumor microenvironment. Furin-inhibited CAR-M therefore represent a second-generation CAR-M therapeutic strategy for solid tumors.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2

Method for detecting biological functions of mesenchymal stem cells

The invention relates to the technical field of biology, in particular to a method for detecting biological functions of mesenchymal stem cells. The invention provides a method for evaluating the functions of mesenchymal stem cells by using the combination of surface molecules CD155 and secretory factors IDO, which is different from the conventional detection method and is characterized in that the biological functions of the cells are rapidly judged by detecting the surface CD155 of the mesenchymal stem cells through flow cytometry and detecting the concentration of cytokines IDO through an ELISA (Enzyme-Linked Immuno Sorbent Assay) method. The biological functions refer to proliferation, differentiation, adhesion, anti-apoptosis, factor secretion and anti-inflammatory functions of the mesenchymal stem cells, and the method is rapid and accurate, has a wide application prospect and is worthy of popularization and application.
Owner:PUHUA SAIER BIOMEDICAL TECH CO LTD

Method for producing organoid and organoid

Provided is a technique for producing an organoid that is larger in size and more functionally excellent than conventional organoids. The present invention employs a method for producing an organoid, the method comprising: a step (A1) for culturing an organoid, in which an organoid produced from undifferentiated cells, mesenchymal cells, and vascular cells that differentiate into a first organ is brought into a secretion factor secreted from a second organ; and a step (A2) for culturing the organoid cultured in the step (A1). In the step (A1) and the step (A2), the dissolved oxygen partial pressure of a medium in contact with the organoid is 20% or less. The dissolved oxygen partial pressure of the medium in contact with the organoid in the step (A1) is lower than the dissolved oxygen partial pressure of the medium in contact with the organoid in the step (A2).
Owner:THE UNIV OF TOKYO

Method for domesticating HUVECs to simulate colorectal cancer vascular endothelial cells and domesticating culture medium

The invention relates to the technical field of tumor in-vitro models, in particular to a method for domesticating HUVECs to simulate colorectal cancer vascular endothelial cells and a domestication culture medium. The colorectal cancer vascular endothelial cell specific secretion factor IGFBP5 is obtained through single cell sequencing analysis, the IGFBP5 and the HUVECs are added into an HUVECs complete culture medium, an in-vitro model with better tumor vascular characteristics can be formed, colorectal cancer blood vessels are better simulated, and a more simulated colorectal cancer in-vitro model is constructed.
Owner:NANJING GENERAL HOSPITAL NANJING MILLITARY COMMAND P L A

Media, methods, cells and secreted factors for stem cell culture and therapy

To provide novel culture medium compositions, stem-cell culture methods and therapy methods for the purpose of inducing, activating or priming naive multipotent stem cells, which are mesenchymal stem cells in some embodiments, into discrete, multipotent, type 1 or type 2 cell phenotypes that selectively promote or suppress inflammation and immunity.SOLUTION: Described herein are methods and culture media useful for inducing polarization in multipotent stem cells. Additionally described herein are multipotent cells produced by the methods and culture media of this disclosure that are useful therapeutic agents. Also described herein are extracellular vesicles and factors secreted by multipotent cells produced by the methods and culture media of this disclosure that are useful therapeutic agents.SELECTED DRAWING: None
Owner:SANBIO INC

Micro-fluidic chip for interaction of intercellular secretory factors and application of micro-fluidic chip

The invention belongs to the technical field of micro-fluidic chips, and particularly relates to an intercellular secretion factor interaction micro-fluidic chip and application thereof. The microfluidic chip comprises an intermediate culture layer, a first culture layer and a second culture layer, wherein the first culture layer and the second culture layer are detachably connected with the intermediate culture layer respectively; culture chambers are arranged in the middle culture layer, the first culture layer and the second culture layer, and a plurality of micro-channels communicated with the culture chambers are uniformly arranged on the periphery of each culture chamber; the culture chambers in the middle culture layer, the first culture layer and the second culture layer are mutually communicated through the micro-channels; independent perfusion channels and liquid outlet channels are arranged in the middle culture layer, the first culture layer and the second culture layer, and each independent perfusion channel and each independent liquid outlet channel are connected with an independent liquid inlet and an independent liquid outlet which are formed in each culture layer. The micro-fluidic chip provided by the invention is simple in structure, can realize separation of multiple cells in time and space at the same time, and meets the in-situ observation requirements.
Owner:SHENZHEN LONGGANG DISTRICT PEOPLES HOSPITAL

In-vitro maturation culture solution for giant panda oocyte and application thereof

PendingCN122128224AGerm cellsPANDASAdenosine
This invention relates to an in vitro maturation culture medium for giant panda oocytes and its application, belonging to the field of biotechnology. The invention discloses an in vitro maturation culture medium for giant panda oocytes, which simultaneously adds the following three paracrine factors to the basal culture medium: adenosine diphosphate riboylation factor 6 (ARF6); ciliary neurotrophic factor (CNTF); and hepatocyte growth factor (HGF). The invention also provides the application of the aforementioned in vitro maturation culture medium for giant panda oocytes, specifically for the in vitro maturation culture of giant panda oocytes. This invention effectively addresses the shortcomings of existing in vitro oocyte maturation technologies, significantly improves oocyte maturation quality, is simple to operate, and has high safety, providing a key technological reserve for assisted reproduction in giant pandas.
Owner:CHENGDU RES BASE OF GIANT PANDA BREEDING

Establishment method of naturally immortalized pilose antler regeneration bud cell line and engineering preparation method of functional factors of naturally immortalized pilose antler regeneration bud cell line

The invention discloses an establishment method of a naturally immortalized pilose antler regeneration bud base cell line and an engineering preparation method of functional factors of the naturally immortalized pilose antler regeneration bud base cell line, and belongs to the technical field of biology. The method comprises the following steps: obtaining pilose antler regeneration bud bases, performing primary culture and identification on regeneration bud base cells, screening to obtain dominant growth cell strains, performing engineering preparation and purification on secretion factors of the regeneration bud base cells by adopting a cell culture bioreactor, and identifying the activity of the factors. According to the method, the pilose antler regeneration bud cell line which is high in activity, high in proliferation rate, capable of retaining bud cell attributes and capable of being subcultured for at least 200 times is preferably selected, so that the natural immortalization of the cells is realized, and the biological characteristics of the immortalization of the pilose antler regeneration bud cell are identified. Meanwhile, the problems that the pilose antler regenerated bud-based cells cannot be directly applied to the safety and ethics of a human body and are high in cost and difficult to produce on a large scale are solved by a method for producing functional factors, and the pilose antler regenerated bud-based cell secretion factors with biological activity are prepared in an engineering manner and purified.
Owner:长春科技学院 +1

Cell culture application method using separation pore microwell plate

Automated methods for horizontal co-culture of cells using a single separation well microwell plate are provided. The present disclosure also provides improved methods of quantifying secreted factors from cultured cells, as well as methods of isolating target cells from organoids in a single isolation well microplate.
Owner:MOLECULAR DEVICES AUSTRIA GMBH +1

Prophylactic and / or therapeutic agent for skin disorder

PCT designated stageWO2026105679A1Organic active ingredientsMicrobiological testing/measurementMelanocytePhotosensitive skin
Provided is a prophylactic and / or therapeutic agent for photodermatitis caused by light exposure. This prophylactic and / or therapeutic agent for a skin disorder caused by light exposure contains an inhibitor for cellular senescence-associated secretory phenotype factors (SASP factors) as an active ingredient. As a result of exploring responses to light exposure in melanocytes and comprehensively analyzing molecules that can be therapeutic target seeds related to the skin disorder, it was shown that cellular senescence occurs in melanocytes after light exposure. In melanocytes having undergone cellular senescence, enhanced expression of an SASP factor group was observed, and this led to the finding that an inhibitor for SASP factors is effective for preventing and / or treating the skin disorder.
Owner:KOBE UNIV +1

Method for studying the mechanism of the influence of monocyte remodeling based on the inflammatory microenvironment of the bone marrow on tumor cells

The application discloses a research method for tumor cell influence mechanism of monocyte remodeling based on bone marrow inflammatory microenvironment, and relates to the technical field of tumor treatment; and comprises the following steps: S1, providing bone marrow plasma from a classic myeloproliferative neoplasm patient; S2, placing primary CD14+ monocytes from a healthy donor in an in-vitro culture system containing the bone marrow plasma, inducing phenotype remodeling of the monocytes, and obtaining the remodeling monocytes. The application establishes CD163+CD206+ double-positive remodeling monocytes as a new target for MPN treatment; through comparison experiments of direct co-culture and indirect co-culture by Transwell, it is confirmed that the promotion effect of the remodeling monocytes on HEL cell proliferation strictly depends on physical contact between cells, rather than soluble secreted factors; and the application provides a theoretical basis for developing new antibody drugs or small molecule inhibitors for blocking cell-cell interaction.
Owner:CHONGQING MEDICAL UNIVERSITY

Application of skin organoid conditioned medium in promoting tissue repair of acute skin injury

The application relates to the technical field of cell biology, and particularly relates to application of a skin organoid conditioned medium in promoting repair of acute skin damage tissue, to a human skin organoid in-vitro model, to collection of a skin organoid conditioned medium (SOCCM) cultured for 6-8 days, enrichment of a variety of secretory factors related to skin repair, inflammation control and angiogenesis in the skin organoid conditioned medium, formation of a characteristic secretome, in-vivo and in-vitro experiment verification that the skin organoid conditioned medium can significantly promote fibroblast migration, vascular endothelial cell lumen formation, accelerate acute skin damage wound closure, promote collagen ordered deposition and tissue remodeling, and improve skin damage repair quality. The application avoids tumorigenic and immunological rejection risks of the organoid / stem cell transplantation, provides a new treatment strategy for repair of the acute skin damage, and can also be applied to repair of chronic non-healing wounds and repair of skin light damage and the like.
Owner:RENHAI MEDICAL TECHNOLOGY (JIANGSU) CO LTD